Sign up for Table of Contents Alerts.
Email this page
Print this page
Clinical Case Report
Fatal Rhabdomyolysis as a Complication of ET-743 (Yondelis) Chemotherapy for Sarcoma: Case Report and Literature Review
Amy Skorupa, Matthew Beldner, Andrew Kraft and Alberto J. Montero
volume 6 | issue 7
July 2007Pages: 1015 - 1017
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.
Authors
Amy Skorupa
Medical University of South Carolina, Charleston, South Carolina USA
Matthew Beldner
Medical University of South Carolina, Charleston, South Carolina USA
Andrew Kraft
Medical University of South Carolina, Charleston, South Carolina USA
Alberto J. Montero
University of South Carolina, Charleston, SC
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.